Mitotic arrest deficient 2 (Mad2) belongs to the spindle assembly checkpoint (SAC), a mechanism that blocks progression of the cell cycle until microtubule attachment to kinetochores is complete. It has been found to be involved in the resistance of cancer cells to "anti-mitotic" drugs such as paclitaxel. Mad2 controls meiotic progression, but its role during sea urchin development had never been investigated. Furthermore, the existence of a SAC in this species had never been proved. The present data show that a Mad2 protein, highly homologous to that of humans, is expressed in this species. Mad2 expression increases during development, becoming confined to the endomesoderm at gastrula stages. The level of Mad2 expression is enhanced in embryos that do not gastrulate after treatment with anti-mitotic drugs, lithium or inhibition of the ERK pathway. Mis-aligned and lagging chromosomes were induced after injection of an anti-Mad2 antibody or a Mad2 morpholino. Our results point to the role of a non-canonical SAC involving Mad2 in the control of mitotic divisions of the sea urchin embryo.
Mad2 belongs to the spindle assembly checkpoint (SAC) that blocks progression of cell cycles until microtubule (MT) attachment to kinetochores is complete. Depletion of Mad2 usually accelerates the metaphase-anaphase transition and perturbs mitosis in various cultured cell types. In contrast, Mad2 overexpression induces a variety of mitotic alterations in various types of cells and is a commonly observed event in human cancers (Lischetti and Nilsson, 2015) . Mad2 is essential for mouse development from meiotic progression (Touati and Wassmann, 2016) to gastrulation (Dobles et al., 2000) . However, Mad2-null Drosophila are viable and fertile and cellular division occurs properly despite having no SAC (Buffin et al., 2007) .
Drugs affecting MTs such as paclitaxel and vinblastine trigger activation of the SAC leading to cell cycle arrest and ultimately cell death. These are extensively used in cancer treatments and are referred to "anti-mitotics". Nocodazole and colchicine also affect MTs but their toxicities have curtailed their development as anticancer agents. Acquired resistance is a crucial issue for the therapeutic use of most anti-mitotics, a process likely linked to alterations in Mad2 expression (Bargiela-Iparraguirre et al., 2014) .
We considered whether the sea urchin model could be useful to assess Mad2 expression dynamics. Treatment of sea urchin embryos with anti-mitotics during the first mitosis inhibits division (Sluder et al., 1997 , Strickland et al., 2005 , but the effect of long time treatments has not been investigated. This study was necessary bound to the question concerning the existence of a SAC mechanism, which is still debated in this species (Sluder et al., 1997) . The present data suggest that Mad2 belongs to a non-canonical SAC, a system that involves the ERK cascade and controls mitosis as previously reported . Since Mad2 expression has been correlated with epithelial-mesenchymal transition (EMT), a process used by cells that metastasize (Nakaya and Sheng, 2013) , and that both EMT and Mad2 expression are altered by "anti-mitotic" drugs, we propose that the sea urchin embryo could be useful to study how MT-disrupting agents affect Mad2 expression.
Results

Expression of mitotic arrest deficient-2 (MAD2) during development
The sequence of the translated Mad2 protein is highly similar to SP-MAD2A of S. purpuratus (SPU_016042) and to that of human ( Fig.1 ). This allowed us to use a commercial anti-Mad2 Ab raised against the human protein. IF stainings (Fig.2) show that Mad2 is minimally expressed in the unfertilized egg (t0), then its expression increases in the fertilized embryo (1h) to remain the same in each blastomere at least to the 16 cell stage (not shown). By the blastula stage (20h), Mad2 is uniformly expressed. However at the gastrula stage (28h), only the vegetal pole shows a faint expression ( Fig.2A, 28h b and b'). These results corroborated those obtained by WISH ( Fig.2B , 28h b and b'). Therefore, Mad2 expression increases during development and is predominantly found in the endomesoderm at the gastrula stage.
Vegetalization of the embryo after treatment with 20 mM LiCl (Poutska et al., 2007 ) or 5 mM U0126 (Röttinger et al., 2004 expands Mad2 expression territory as it does for various genes showing a similar early expression pattern (Poutska et al., 2007) .
WISH staining shows a strong Mad2 expression over the entire vegetilized embryo (Fig.3A ). This is confirmed by RT-PCR analysis ( Fig.3B ). Mad2 expression increases with the time of LiCl treatment ( Fig.3Ba ). A 2.7 +/-0.5 (n=6) and 1.8 +/-0.4 (n=5) fold increase in Mad2 expression was measured in embryos treated for 28h with 20mM LiCl or 5 mM U0126, respectively ( Fig. 3Bb ).
Role of Mad2 during development
Unfertilized eggs from four different batches were injected with a Mad2-Ab as a blocking reagent, fertilized and then allowed to develop. None of 59 injected eggs from two different batches divided. In the two others, 26 out of 34 injected eggs failed to divide. These embryos showed diverse mitotic alterations ( Fig.4) at the 4-cell ( Fig.4A ) or 8-cell stages ( Fig.4B ) compared to control embryos, such as chromosomes lagging ( Fig.4Aa -c), abnormal metaphase plate ( Fig.4B1a -b) or aberrant chromosome arrangements ( Fig.4B2a-b ). Eggs that could divide once remained blocked at the 2-cell stage with an aberrant chromosome segregation . 95 % of the non-injected embryos or embryos injected with a control antibody (anti-presenilin 2 Ab raised against a sequence without similarity found in the sea urchin genome) divided normally, indicating a specific effect of the anti-Mad2 Ab (not shown).
We then injected a Mad2-Mo as a complementary knockdown strategy. A rescue experiment was performed by co-injecting the Injection of the Mad2-Mo induced mitosis arrest in all batches of eggs at a time that varied across batches ( Fig.5A ). In Exp1 and Exp2, more than 60% of eggs did not divide at all. In Exp3 and Exp4, 10-26 % embryos divided three times, giving 8-16 cells embryos without obvious alterations. The remaining embryos showed an aberrant number of dividing blastomeres with alterations in chromosome segregation. In all batches, all embryos injected with the Mad2-Mo did not reach a normal 32-cell stage and all died 5h to 6h following fertilization (not shown). The rescue experiment was conducted on eggs from Exp.3/4 ( Fig.5C ). Injection of the Mad2-mRNA alone had no effect ( Fig.5C-1 ) while aberrant chromosome segregation occurred in a high percentage in eggs injected with the Mad2-Mo ( Fig.5A and Fig.5C -2). Co-injection of the Mad2-mRNA and the Mad2-Mo (rescue) increased the % of third division obtained after injection of the Mad2-Mo only (Fig.5A ), resulting in more than 50 % embryos able to progress normally to the 16-cells stage ( Fig.5C-3) . Similar alterations were observed upon anti-Mad2 Ab injection, although slightly less pronounced/ delayed phenotypes appearing (Fig.4) .
In order to test whether Mad2-Mo injection impacts Mad2 synthesis, eleven embryos were injected with Mad2-Mo and then immunostained for Mad2 ( Fig.5D ). Seven embryos showed obvi-ous altered development, containing 4-8 blastomeres of various sizes. In these, the Mad2 staining level varied from 75 % to 20% of that measured in 2 or 4 cell stage control embryos from the same experiment (not shown) as seen in Fig.5 .
Unfertilized eggs seem therefore to contain a maternal pool of Mad2, the level of which varies across batches. This may be sufficient to accomplish the first three mitotic divisions but a de novo synthesis is required to sustain long term development.
Effect of anti-mitotic drugs on Mad2 expression
A dose-response assay was performed by adding, 10 min post-fertilization, nocodazole, colchicine, vinblastine or paclitaxel at various concentrations up to 5 mM. Three batches of eggs were tested and gave similar results. Fig. 6A shows the developmental chronology. Nocodazole had a maximal effect at 1 mM, a concentration at which embryos remained at NEB until they begun dying 7h after fertilization, the entire population being dead at 22h (Fig.6B) . A 5 mM treatment with paclitaxel, colchicine or vinblastine did not alter the first divisions ( Mad2 expression in treated embryos was further assayed except in nocodazole treated embryos that do not divide. Compared to control blastula (Fig.7Ab ), the IF level increased after treatment with 5 mM of paclitaxel ( Fig.7Bb) , colchicine ( Fig.7Bb ) or vinblastine ( Fig.7Cb) . A similar increase in Mad2 transcription is seen by WISH studies (Fig.8A) . While only the vegetal pole is stained in non-treated embryos at the gastrula stage, treated embryos are strongly and uniformly stained. This finding was confirmed by RT-PCR performed on four different batches (Fig.8B ). It must be pointed that the sensitivity to each drug varies across batches (Fig.8Bb) .
Finally, treatment with these anti-mitotic drugs affected ERK phosphorylation. 1mM nocodazole arrested the first cell cycle (Fig.6B ) without altering P-ERK inactivation (not shown). In the three different embryos batches, P-ERK levels increased significantly in embryos treated with vinblastine and paclitaxel compared to controls (Fig.9A,B) . 
Discussion
Several results indicate that Mad2 transcription and translation occur at early developmental stages in sea urchins. Indeed, Mad2 cDNA clones can be found in the P. lividus library generated from unfertilized eggs (Pl_EGG) or gastrula stages (Pl_GASPLU). Our IF, WISH and RT-PCR experiments also support this early expression. We . The anti-Mad2 Ab we used may only label native form(s) that are bound or not to kinetochores and may diffuse in the cytoplasm as reported in rat oocytes (Zhang et al., 2004) . This could account for the uniform Mad2 expression that we observed by IF until the blastula stage. Mad2 depletion by Ab or morpholino injections leads to misaligned and lagging chromosomes and blocks division. This phenotype is expected after SAC activation but not inhibition. How to interpret these results? Mad2 and Bub3 are both expressed in sea urchin and highly homologous to human ones. In contrast, Mad1 and BubR1 are far less conserved and only one Aurora kinase is expressed in the sea urchin S. purpuratus (Table 1, S1). Our data reinforce the idea of a "non-canonical SAC", different from the mammalian one, in the sea urchin embryo as proposed over the last years (Sluder et al., 1997) . This idea was introduced in Giardia intestinalis where Mad2 knockdown also stops mitosis (Vicente and Cande, 2014) .
The maternal amount of the SAC components stocked in oocytes before fertilization may decrease during oocyte aging as reported in mammalians (Touati and Wassmann, 2016) . This would define a starting SAC efficiency that could account for variation across egg batches.
Mad2 is mostly expressed in the endomesoderm and overexperssed in vegetelized embryos. This could be expected as cellular division becomes confined to the endomesoderm and parts of the oral ectoderm after gastrulation (Zhang et al., 2015) . It would be interesting to analyse the efficiency of SAC at later stages.
Our results suggest that anti-mitotic drugs act within a similar range of concentration throughout the embryo, allowing gastrulation under a given threshold. This is not (A,B,C,D) . Results are mean +/-sem of IF level recorded in n embryos.
surprising since MTs control EMT during gastrulation (Stephens et al., 1989) . However, gastrulation failure may also be due to other processes requiring MT function. Finally, the delayed development upon 6hr of treatment may be due to mechanisms unrelated to the SAC itself as these drugs could interfere with proteins that bind MTs. This is the case for Disheveled (Dsh) that binds MTs and controls the Wnt pathway which establishes the animal-vegetal axis (Torres and Nelson, 2000) .
No DNA fragmentation was detected in embryos treated with the antimitotic drugs even when displaying obvious phenotypic manifestations (S2). Such difficulty to assess DNA fragmentation has been reported (Houel-Renault et al., 2013) . Finally, the sen- (Exp 1-4) of semi-quantitative RT-PCR performed as explained in Fig. 3B . sitivity to each drug varies across embryo batches. As discussed above, this may be due to a variety of parameters including seasonal heterogeneity, time of gametes retention in the gonads etc. For example, Cameron et al., (1993) reported a "considerable batchto-batch variability" in the frequency of gastrula arrest that occurs after injection of (5HT-R) mRNA into sea urchin blastomeres.
Fertilized sea urchin eggs treated with nocodazole did not form any spindle and did not show increased level of ERK phosphorylation, contrary to fertilized eggs that arrest at entry in mitosis in acidic ASW containing Obviously, different means of arresting the first mitotic divisions do not stimulate a common pathway. The diversification of ERK roles during development (Röttinger et al., 2006) may explain the increase in ERK phosphorylation seen at later stages in embryos treated with the antimitotic drugs.
Mechanisms that modify Mad2 expression in cancer cells are not understood. The gene regulatory networks described in this model are the best understood among animal models, particularly that regulating gastrulation (Hinman and Cheatle Jarvela, 2014) , which requires the process of EMT. The study of Mad2 expression in the sea urchin embryo may help understanding how it is altered by antimitotic drugs, controlled by the MEK/ERK cascade or modified during the EMT associated with gastrulation, a crucial step of development that involves sets of events common to those described in cells that metastasize (Nakaya and Sheng, 2013) .
Materials and Methods
Manipulation of the Paracentrotus lividus gametes, Western blot (WB), immunofluorescence (IF) labelling, microscopy observations and quantification of WB bands were performed as previously described (Houel-Renault et al., 2013) . Mad2 immunostaining level was quantified by Image J and normalized by comparison to the value determined in control eggs and/or blastomeres arbitrarily taken as 1.
Stock solutions of nocodazole (25 mM), paclitaxel (10 mM), vinblastine (10 mM) and colchicine (10 mM) were prepared in DMSO. Vegetalization was induced by transferring embryos in ASW containing 20 mM LiCl (1M stock solution in distilled water) or 5 mM U0126 (Calbiochem, 15 mM stock solution in DMSO) after the first mitosis had occurred and leaving them to develop in these solutions.
We used a phospho-p42/44 ERK Ab (#9106, Cell Signaling Tech), an anti-a tubulin Ab (#CP06, Calbiochem), an anti-Mad2 antibody (Biolegend,#602101) with an anti-rabbit FITC Ab (Jackson), an anti-presenilin 2 (H76, sc-7861, Santa Cruz Tech) and an anti-tubulin Ab YL1/2 (Chemicon) with an anti-rat FITC IgG (Jackson ImmunoResearch) to label spindles.
To obtain an in situ Mad2 probe, we used a clone (PK0AAA6YG11RM1) from a Paracentrotus lividus cDNA library (http://octopus.obs-vlfr.fr). The translated sequence of the insert was transferred in pBluescript II KS+ using the pair of primers Mad2-F (5'-cgcggatccCGGGTGTACAACAAACAAC-GAA-3') and Mad2-R (5'-cccaagcttTCCCATCCATGAGTTTGTAAGACA 3'). We used BLASTP (http://www.ncbi.nlm.nih.gov/BLAST/) to compare sequences. WISH probes were synthesized and labelled with digoxigenin-11-UTP (Roche) following a protocol described by Duboc et al., (2005) .
For semi-quantitative RT-PCR, total RNA was purified from dry pellets with an RNeasy Plus Micro Kit (Qiagen). RT was performed using the SuperScript II RT-kit (Invitrogen) and reverse (RV) primers (see below) of both Mad2 and S6 (used as internal control). S6 sequence was retrieved from the same Paracentrotus lividus cDNA library. PCR was performed with a GoTaq G2 Flexi DNA Polymerase-kit (Promega) with couples of RV and forward (FW) primers of either Mad2 or S6. Bands were quantified by Image J, normalized by comparison to S6 and then expressed relative to the value of control embryos taken as 1. Primers are as follows:
FW-Mad2: AAGGCATACCTGTCATCGGTAATGG RV-Mad2: AAGTCCTTGTCGGTGTAAATGAGCA FW-S6: GATGCGTTGAAGAGGTCACTTACTG RV-S6: GATGTCACGACGGAAGTACTCGTTT Injections were conducted as previously described (Houel-Renault et al., 2013) with a 1/10 dilution of the anti-Mad2 Ab stock solution, 0.15 mM Mad2-Morpholinos (Mad2-Mo and Mad2-Mc) and/or 0.15 mg/ml Mad2 mRNA which is in the same range than RNA amounts injected by others (Duboc et al., 2005) . All were diluted in distilled water containing 2mM carboxyfluorescein to visualize injection.
The Mad2-Mo (TCGTTGTTTGTTGTACACCCGCCAT), which targets a region 120 nucleotides 5' to the putative start codon, and a standard negative control morpholino (Mad2-Mc, CCTCTTACCTCAGTTACAATT-TATA), which targets a human beta-globin intron mutation) were obtained from Gene Tools.
Synthetic mRNA was synthesised as follows: The entire Mad2 ORF was amplified from the same clone used for ISH as described above and using the following primers: 5'-CGGAATTCCATGTACAAGCTACCCCT-GCTAAC-3'and 5'-CCGCTCGAGTTATATCCCATCCATGAGTTTGTAAG-3' and subcloned into the pCS2FLAG vector (www.addgene.org/16331/) at the EcoRI/XhoI restriction sites. Synthetic mRNA was synthesised with a mMachine kit (Life technologies).
No carboxyfluorescein was used when Mad2 immunostaining was performed on embryos injected with the Mad2-Mo. Embryos were treated with ATAZ, fertilized, deposited on a polylysine petri dish labelled with a grid in order to identify the injected eggs, and then microinjected between 10 and 30 mins after sperm addition. IF was performed after fixation of embryos as described above.
Cell death was detected on PFA fixed embryos using a kit (Roche, Cat. No 11 684 795 910). A positive control was performed as described by the manufacturer. 
